Lamotrigine offers higher net health benefits and is more cost-effective than levetiracetam and zonisamide as first-line focal epilepsy treatment
1. Lamotrigine offered greater clinical benefit, fewer adverse reactions, and higher cost-utility normalized to quality-adjusted life years compared to levetiracetam ...